Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
50M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
12.5K
-
Shares change
-
-8.03K
-
Total reported value, excl. options
-
$154K
-
Value change
-
-$71.6K
-
Number of buys
-
1
-
Number of sells
-
-1
-
Price
-
$12.25
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (KALV) as of Q4 2023
2 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q4 2023.
KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (KALV) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.5K shares
of 50M outstanding shares and own 0.03% of the company stock.
Largest 10 shareholders include VR Adviser, LLC (4.09M shares), Frazier Life Sciences Management, L.P. (3.62M shares), TANG CAPITAL MANAGEMENT LLC (3.44M shares), TCG Crossover Management, LLC (3.4M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (2.68M shares), BlackRock Inc. (2.24M shares), Saturn V Capital Management LP (1.81M shares), VANGUARD GROUP INC (1.78M shares), Boxer Capital, LLC (1.65M shares), and Jefferies Financial Group Inc. (1.08M shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.